GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-09-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fcell.2020.562522/full |
| id |
doaj-3a228b487af148a39d865b90e0d28e51 |
|---|---|
| record_format |
Article |
| spelling |
doaj-3a228b487af148a39d865b90e0d28e512020-11-25T03:47:12ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2020-09-01810.3389/fcell.2020.562522562522GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting CompoundsKathrin Brockmann0Kathrin Brockmann1Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, GermanyGerman Center for Neurodegenerative Disease (DZNE), Bonn, GermanyWith disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson’s disease and dementia with Lewy bodies.https://www.frontiersin.org/article/10.3389/fcell.2020.562522/fullGBAalpha-synucleindementiaGCaseParkinson |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Kathrin Brockmann Kathrin Brockmann |
| spellingShingle |
Kathrin Brockmann Kathrin Brockmann GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds Frontiers in Cell and Developmental Biology GBA alpha-synuclein dementia GCase Parkinson |
| author_facet |
Kathrin Brockmann Kathrin Brockmann |
| author_sort |
Kathrin Brockmann |
| title |
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds |
| title_short |
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds |
| title_full |
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds |
| title_fullStr |
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds |
| title_full_unstemmed |
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds |
| title_sort |
gba-associated synucleinopathies: prime candidates for alpha-synuclein targeting compounds |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Cell and Developmental Biology |
| issn |
2296-634X |
| publishDate |
2020-09-01 |
| description |
With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson’s disease and dementia with Lewy bodies. |
| topic |
GBA alpha-synuclein dementia GCase Parkinson |
| url |
https://www.frontiersin.org/article/10.3389/fcell.2020.562522/full |
| work_keys_str_mv |
AT kathrinbrockmann gbaassociatedsynucleinopathiesprimecandidatesforalphasynucleintargetingcompounds AT kathrinbrockmann gbaassociatedsynucleinopathiesprimecandidatesforalphasynucleintargetingcompounds |
| _version_ |
1724502972848668672 |